Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Medicinova, Inc. (NASDAQ: MNOV).

Full DD Report for MNOV

You must become a subscriber to view this report.


Recent News from (NASDAQ: MNOV)

MediciNova Announces FDA Grants Orphan Drug Designation to MN-166 (ibudilast) for Glioblastoma
LA JOLLA, Calif., Oct. 04, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that the U.S. Food and Drug Administration (FDA) has grant...
Source: GlobeNewswire
Date: October, 04 2018 19:00
MediciNova up 2% premarket on potential approval path for MN-166 in ALS
Thinly traded MediciNova (NASDAQ: MNOV ) is up  2%  premarket on light volume on the heels of its announcement that, based on FDA feedback, only one Phase 3 study may be required to support a U.S. marketing application for MN-166 (ibudilast) for amyotrophic lateral sclerosis (ALS...
Source: SeekingAlpha
Date: September, 26 2018 07:33
MediciNova Announces Positive FDA Feedback Regarding Phase 3 Plan for MN-166 (ibudilast) in ALS
LA JOLLA, Calif., Sept. 25, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received positive feedback from the FDA (U.S. Foo...
Source: GlobeNewswire
Date: September, 25 2018 19:00
MediciNova to Attend the Morgan Stanley Global Healthcare Conference in New York
LA JOLLA, Calif., Sept. 04, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova will attend the Morgan Stanley Global He...
Source: GlobeNewswire
Date: September, 04 2018 19:00
Week 36 Breakout Forecast: Short-Term Picks To Give You An Edge
Breakout Forecast Selections for Week 36: Market conditions have generated a strong increase in positive breakout momentum and a decline negative momentum this week. The positive momentum gauge continues higher to 65 up from a value of 51 at the end of last week. The yellow positive mome...
Source: SeekingAlpha
Date: September, 01 2018 13:03
Your Daily Pharma Scoop: Karyopharm Buoyed, MediNova Succeeds, Ardelyx's Publication
Stocks in the News Karyopharm up 4% ahead of presentation of selinexor data Discussion Karyopharm Therapeutics ( KPTI ) reported that they plan to present, at the Society of Hematologic Oncology ((SOHO)) Annual Meeting in Houston, data from their Phase 2b STORM study evaluating sel...
Source: SeekingAlpha
Date: August, 31 2018 12:18
MediNova up 9% after hours on successful mid-stage study of ibudilast in MS
Thinly traded MediNova (NASDAQ: MNOV ) is up  9%  after hours on light volume on the heels of the  release of results from a Phase 2 clinical trial evaluating MN-166 (ibudilast) in patients with progressive multiple sclerosis (progressive MS). The data were just published i...
Source: SeekingAlpha
Date: August, 29 2018 20:29
MediciNova Announces the Publication of Results of the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS in the New England Journal of Medicine
LA JOLLA, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the New England Journal of Medicine has published re...
Source: GlobeNewswire
Date: August, 29 2018 17:00
National Institute on Alcohol Abuse and Alcoholism Awards R01 Research Grant to UCLA for Phase 2b Clinical Trial of MediciNova's MN-166 (ibudilast) in Alcohol Use Disorder
LA JOLLA, Calif., Aug. 20, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the National Institute on Alcohol Abuse and Alcoholi...
Source: GlobeNewswire
Date: August, 20 2018 19:00
Report: Exploring Fundamental Drivers Behind MediciNova, Dermira, FRP, BiondVax Pharmaceuticals, The Descartes Systems Group, and American Software - New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Aug. 20, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of MediciNova, Inc. (NASDAQ:MNOV), Dermira, Inc. (NASDAQ:DERM), FRP Holdings...
Source: GlobeNewswire
Date: August, 20 2018 07:50

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0811.3711.5411.6511.3731,919
2018-05-1710.5010.3910.5010.14109,132
2018-02-2610.9811.0911.1010.60150,505
2018-02-2311.0010.9111.0110.69156,836
2018-02-2210.6010.6210.8610.56106,659

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-184,05312,65632.0243Cover
2018-12-1713,45323,70856.7446Short
2018-12-144,46413,24333.7084Cover
2018-12-137,6379,63779.2467Short
2018-12-123,53117,06620.6903Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on MNOV.


About Medicinova, Inc. (NASDAQ: MNOV)

Logo for Medicinova, Inc. (NASDAQ: MNOV)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $417,460,091 - 05/11/2018
  • Issue and Outstanding: 41,129,073 - 04/24/2018

 


Recent Filings from (NASDAQ: MNOV)

Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: May, 17 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: May, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 26 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 26 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 26 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: April, 25 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 21 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 14 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: February, 13 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: February, 08 2018

 

 


Daily Technical Chart for (NASDAQ: MNOV)

Daily Technical Chart for (NASDAQ: MNOV)


Stay tuned for daily updates and more on (NASDAQ: MNOV)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: MNOV)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in MNOV is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of MNOV and does not buy, sell, or trade any shares of MNOV. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/